Oliver Murch

Oliver Murch

Auto-generated profile, based on publicly available information

Oliver Murch

Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2005 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
MCMarika Collin
Marika Collin
FAFarhana B M Anuar
Farhana B M Anuar
OMOliver Murch
Oliver Murch
MBMadhav Bhatia
Madhav Bhatia
PMPhilip K Moore
Philip K Moore
CTChristoph Thiemermann
Christoph Thiemermann

9 November 2006 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
OMOliver Murch
Oliver Murch
MCMarika Collin
Marika Collin
CHCharles J. Hinds
Charles J. Hinds
CTChristoph Thiemermann
Christoph Thiemermann

1 September 2008 in Shock
Verified
Journal Article
Closed access
Massimo CollinoMassimo Collino
Massimo Collino
CTChristoph Thiemermann
Christoph Thiemermann
Raffaella MastrocolaRaffaella Mastrocola
Raffaella Mastrocola
MGMargherita Gallicchio
Margherita Gallicchio
EBElisa Benetti
Elisa Benetti
RFRoberto Fantozzi
Roberto Fantozzi
The serine/threonine glycogen synthase kinase 3β (GSK-3β) is abundant in the central nervous system, particularly in the hippocampus, and plays a pivotal role in the pathophysiology of a number of diseases, including neurodegeneration. This study was designed to investigate the effects of GSK-3β inhibition against I/R injury in the rat hippocampus. Transient cerebral ischemia (30 min) followed by 1 h of reperfusion significantly increased generation of reactive oxygen species and modulated superoxide dismutase activity; 24 h of reperfusion evoked apoptosis (determined as mitochondrial cytochrome c release and Bcl-2 and caspase-9 expression), resulted in high plasma levels of TNF-α and increased expression of cyclooxygenase-2, inducible nitric oxide synthase, and intercellular adhesion molecule-1. The selective GSK-3β inhibitor, 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), was administered before and after ischemia or during reperfusion alone to assess its potential as prophylactic or therapeutic strategy. Prophylactic or therapeutic administration of TDZD-8 caused the phosphorylation (Ser9) and hence inactivation of GSK-3β. Infarct volume and levels of S100B protein, a marker of cerebral injury, were reduced by TDZD-8. This was associated with a significant reduction in markers of oxidative stress, apoptosis, and the inflammatory response resulting from cerebral I/R. These beneficial effects were associated with a reduction of I/R-induced activation of the mitogen-activated protein kinases JNK1/2 and p38 and nuclear factor-κB. The present study demonstrates that TDZD-8 protects the brain against I/R injury by inhibiting GSK-3β activity. Collectively, our data may contribute to focus the role of GSK-3β in cerebral I/R.

15 March 2007 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
NCNeil Cartwright
Neil Cartwright
OMOliver Murch
Oliver Murch
SMShaun K. McMaster
Shaun K. McMaster
MPMark J. Paul-Clark
Mark J. Paul-Clark
DHDavid A. van Heel
David A. van Heel
JMJane A. Mitchell
Jane A. Mitchell
Rationale: NLRs (nucleotide oligomerisation domain [NOD] proteins containing a leucine-rich repeat) are cytosolic pattern recognition receptors. NOD1 senses diaminopimelic acid–containing peptidoglycan present in gram-negative bacteria, whereas NOD2 senses the muramyl dipeptide (MDP) present in most organisms. Bacteria are the most common cause of septic shock, which is characterized clinically by hypotension resistant to vasopressor agents. In animal models, gram-negative septic shock is mimicked by lipopolysaccharide (LPS), which signals through Toll-like receptor 4 (TLR4) and its adaptor MyD88. The role of NLRs in the pathophysiology of septic shock is not known. Objectives: To compare the effects of selective NOD1 agonists with LPS in vivo. Methods: Vascular smooth muscle cells or whole aortas from wild-type or genetically modified mice were stimulated in vitro with agonists of NOD1 (FK565) or NOD2 (MDP). Vasoconstriction was measured using wire myography. Nitric oxide (NO) formation was measured using Griess reaction and NO synthase-II protein by Western blotting. In vivo, blood pressure, heart rate, and urine output were measured in sham-, LPS-, or FK565-treated animals. Biomarkers of end-organ injury, coagulation activation, NO, and cytokines were measured in plasma. Main Results: FK565, but not MDP, induced NO synthase-II protein/activity in vascular smooth muscle and vascular hyporeactivity to pressor agents. FK565 had no effect on vessels from NOD1−/− mice, but was active in vessels from TLR4−/−, TLR2−/−, or MyD88−/− mice. FK565 induced hypotension, increased heart rate, and caused multiple (renal, liver) injury and dysfunction in vivo. Conclusions: Activation of NOD1 induces shock and multiple organ injury/dysfunction.

1 May 2006 in Shock
Verified
Journal Article
Closed access
LDLaura Dugo
Laura Dugo
MAMaha Abdelrahman
Maha Abdelrahman
OMOliver Murch
Oliver Murch
EMEmanuela Mazzon
Emanuela Mazzon
SCSalvatore Cuzzocrea
Salvatore Cuzzocrea
CTChristoph Thiemermann
Christoph Thiemermann
Glycogen synthase kinase 3β (GSK-3β) is a serine/threonine protein kinase that has recently emerged as a key regulatory switch in the modulation of the inflammatory response. Dysregulation of GSK-3β has been implicated in the pathogenesis of several diseases including sepsis. Here we investigate the effects of 2 chemically distinct inhibitors of GSK-3β, TDZD-8 and SB216763, on the circulatory failure and the organ injury and dysfunction associated with hemorrhagic shock. Male Wistar rats were subjected to hemorrhage (sufficient to lower mean arterial blood pressure to 35 mmHg for 90 min) and subsequently resuscitated with shed blood for 4 h. Hemorrhage and resuscitation resulted in an increase in serum levels of (a) creatinine and, hence, renal dysfunction, and (b) alanine aminotransferase and aspartate aminotransferase and, hence, hepatic injury. Treatment of rats with either TDZD-8 (1 mg/kg, i.v.) or SB216763 (0.6 mg/kg, i.v.) 5 min before resuscitation abolished the renal dysfunction and liver injury caused by hemorrhagic shock. In addition, TDZD-8, but not SB216763, attenuated the increase caused by hemorrhage and resuscitation in plasma levels of the proinflammatory cytokine interleukin 6 and also of the anti-inflammatory cytokine interleukin 10. Neither of the GSK-3β inhibitors however affected the delayed fall in blood pressure caused by hemorrhagic shock. Thus, we propose that inhibition of GSK-3β may represent a novel therapeutic approach in the therapy of hemorrhagic shock.

1 May 2006 in Critical Care Medicine
Verified
Journal Article
Closed access
LDLaura Dugo
Laura Dugo
MCMarika Collin
Marika Collin
DADavid A. Allen
David A. Allen
OMOliver Murch
Oliver Murch
SFSimon J. Foster
Simon J. Foster
CTChristoph Thiemermann
Christoph Thiemermann
Insulin reduces morbidity and mortality among critically ill patients, but the molecular mechanisms of its effect remain unknown. Insulin is a well-known inhibitor of glycogen synthase kinase-3, which may play an important role in systemic inflammation and shock. Here we investigate the role of blood glucose and glycogen synthase kinase-3beta inhibition in the protective effect of insulin on the organ injury/dysfunction associated with excessive systemic inflammation. Prospective, randomized study. University-based research laboratory. Eighty-five anesthetized Wistar rats. Rats received Escherichia coli lipopolysaccharide (1 mg/kg) and Staphylococcus aureus peptidoglycan (0.3 mg/kg) or vehicle intravenously. Insulin (1.4 units/kg intravenously) was administered in the absence or presence of continuous glucose administration (4.5 mg/kg/hr intravenously) either prophylactically or therapeutically. The potent and selective glycogen synthase kinase-3beta inhibitor TDZD-8 (1 mg/kg intravenously) or vehicle (10% dimethyl sulfoxide) was administered either prophylactically or therapeutically. Coadministration of lipopolysaccharide and peptidoglycan resulted in increases in the serum levels of creatinine (indicator of renal dysfunction), alanine aminotransferase, and aspartate aminotransferase (indicators of liver injury) at 6 hrs. Insulin or TDZD-8 similarly attenuated the organ injury/dysfunction caused by lipopolysaccharide and peptidoglycan when given either prophylactically or therapeutically. Continuous glucose administration had no effect on blood glucose levels or organ injury/dysfunction at 6 hrs. Treatment with insulin or TDZD-8 reduced the plasma levels of the proinflammatory cytokine interleukin-1beta. In vitro, insulin or TDZD-8 caused similar reductions in the nuclear factor-kappaB p65 activity and similar increases in the phosphorylation of Ser9 of glycogen synthase kinase-3beta. Therapy with insulin or the potent and selective glycogen synthase kinase-3beta inhibitor TDZD-8 reduced the organ injury/dysfunction caused by lipopolysaccharide and peptidoglycan in the rat. We propose that the inhibitory effect of insulin on the activity of glycogen synthase kinase-3beta contributes to the protective effect of insulin against the organ injury/dysfunction caused by excessive systemic inflammation independently of any effects on blood glucose.